211 related articles for article (PubMed ID: 28389110)
21. [Do orally active factor Xa (FXa) inhibitors have potential as innovative new anticoagulants? Future perspective from preclinical data].
Konishi N; Hiroe K; Kawamura M
Nihon Yakurigaku Zasshi; 2010 Aug; 136(2):88-92. PubMed ID: 20702967
[No Abstract] [Full Text] [Related]
22. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.
Lu G; Pine P; Leeds JM; DeGuzman F; Pratikhya P; Lin J; Malinowski J; Hollenbach SJ; Curnutte JT; Conley PB
PLoS One; 2018; 13(3):e0195122. PubMed ID: 29590221
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and evaluation of isoxazolo[5,4-d]pyrimidin-4(5H)-one derivatives as antithrombotic agents.
Yang J; Su G; Ren Y; Chen Y
Bioorg Med Chem Lett; 2015 Feb; 25(3):492-5. PubMed ID: 25559742
[TBL] [Abstract][Full Text] [Related]
25. Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.
Orwat MJ; Qiao JX; He K; Rendina AR; Luettgen JM; Rossi KA; Xin B; Knabb RM; Wexler RR; Lam PY; Pinto DJ
Bioorg Med Chem Lett; 2014 Aug; 24(15):3341-5. PubMed ID: 24951330
[TBL] [Abstract][Full Text] [Related]
26. Novel Isosteviol-Based FXa Inhibitors: Molecular Modeling, In Silico Design and Docking Simulation.
Gackowski M; Madriwala B; Studzińska R; Koba M
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446638
[TBL] [Abstract][Full Text] [Related]
27. Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct factor Xa inhibitor.
Chi L; Pen YW; Potoczak R; Gibson G; Hicks G; Mertz TE; Janiczek N; Juneau PL; Gallagher K; Leadley R
Pharmacology; 2002 Feb; 64(2):76-83. PubMed ID: 11803247
[TBL] [Abstract][Full Text] [Related]
28. Advances in the Development of Novel Factor Xa Inhibitors: A Patent Review.
Khadse AN; Sharma MK; Murumkar PR; Rajput SJ; Yadav MR
Mini Rev Med Chem; 2018; 18(16):1332-1353. PubMed ID: 29692238
[TBL] [Abstract][Full Text] [Related]
29. Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.
Nagahara T; Yokoyama Y; Inamura K; Katakura S; Komoriya S; Yamaguchi H; Hara T; Iwamoto M
J Med Chem; 1994 Apr; 37(8):1200-7. PubMed ID: 8164262
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, in vivo Anticoagulant Evaluation and Molecular Docking Studies of Bicoumarins Obtained from Furocoumarin Peucedanin.
Lipeeva AV; Khvostov MV; Baev DS; Shakirov MM; Tolstikova TG; Shults EE
Med Chem; 2016; 12(7):674-683. PubMed ID: 26825067
[TBL] [Abstract][Full Text] [Related]
31. A rapid pro-hemostatic approach to overcome direct oral anticoagulants.
Thalji NK; Ivanciu L; Davidson R; Gimotty PA; Krishnaswamy S; Camire RM
Nat Med; 2016 Aug; 22(8):924-32. PubMed ID: 27455511
[TBL] [Abstract][Full Text] [Related]
32. Functional characterisation of vizottin, the first factor Xa inhibitor purified from the leech Haementeria vizottoi.
Oliveira DG; Alvarez-Flores MP; Lopes AR; Chudzinski-Tavassi AM
Thromb Haemost; 2012 Sep; 108(3):570-8. PubMed ID: 22782262
[TBL] [Abstract][Full Text] [Related]
33. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
[TBL] [Abstract][Full Text] [Related]
34. A new peptide (Ruviprase) purified from the venom of Daboia russelii russelii shows potent anticoagulant activity via non-enzymatic inhibition of thrombin and factor Xa.
Thakur R; Kumar A; Bose B; Panda D; Saikia D; Chattopadhyay P; Mukherjee AK
Biochimie; 2014 Oct; 105():149-58. PubMed ID: 25038567
[TBL] [Abstract][Full Text] [Related]
35. Identification of potent orally active factor Xa inhibitors based on conjugation strategy and application of predictable fragment recommender system.
Ishihara T; Koga Y; Iwatsuki Y; Hirayama F
Bioorg Med Chem; 2015 Jan; 23(2):277-89. PubMed ID: 25523211
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
[TBL] [Abstract][Full Text] [Related]
37. New series of 6-substituted coumarin derivatives as effective factor Xa inhibitors: synthesis, in vivo antithrombotic evaluation and molecular docking.
Amin KM; Abdel Gawad NM; Abdel Rahman DE; El Ashry MK
Bioorg Chem; 2014 Feb; 52():31-43. PubMed ID: 24316885
[TBL] [Abstract][Full Text] [Related]
38. Indoline derivatives II: synthesis and factor Xa (FXa) inhibitory activities.
Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Ozeki T; Fujimoto K
Chem Pharm Bull (Tokyo); 2007 Mar; 55(3):393-402. PubMed ID: 17329879
[TBL] [Abstract][Full Text] [Related]
39. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
[TBL] [Abstract][Full Text] [Related]
40. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Honda Y; Kamisato C; Morishima Y
Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
